• Within treated patient group, trends showed improved cognitive and executive functions, improved language comprehension and verbal memory, in comparison to placebo group
• REGEnLIFE’s technology shown to be safe and well-tolerated by patients
• Initial results open up new possibilities for development of brain-gut stimulation device for prevention and treatment of neurodegenerative diseases
![REGEnLIFE presents first results of pilot clinical trial evaluating photobiomodulation technology in the treatment of Alzheimer’s disease](https://ala.associates/wp-content/uploads/2021/03/Guillaume_Blivet_HD-page-001-1080x675.jpg)